Dynavax Reports Upbeat Test Results


Dynavax Technologies Corp. (Nasdaq: DVAX) reported upbeat Phase III results for its hepatitis B vaccine Heplisav sending the stock price soaring 45 cents to close at $1.86.

About this Entry

This page contains a single entry by published on June 3, 2009 2:23 PM.

TiVo Awarded $103 Million was the previous entry in this blog.

JetBlue To Sell 20 Million Common Shares is the next entry in this blog.

Find recent content on the main index or look in the archives to find all content.

Powered by Movable Type 5.12